Author | Lawrence Fong, MD

Articles

Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies

June 15, 2018

Here we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.

Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines

March 15, 2018

ByAmar Patel, MD

Lawrence Fong, MD

The first article in this two-part series will provide an overview of both past and present therapeutic vaccination strategies for the promotion of antitumor immunity against prostate cancer.